Abstract: imotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor (EGFR) can combine with extracellular domain of EGFR and inhibit downstream signaling pathways to prevent tumor growth. Clinical researches show that nimotuzumab has significant antitumor activity in several solid tumors such as squamous cell carcinoma of the head and neck, nasopharyngeal carcinoma, malignant glioma and so on, with advantages of good tolerance and low incidence of rashes.

Key words: Receptor, epidermal growth factor, Antibodies, monoclonal, Neoplasms